PURPOSE: In 1988, we formed a consortium of Brazilian institutions to develop uniform standards for the diagnostic assessment and multidisciplinary treatment of children and adolescents with germ cell tumors. We also implemented the first childhood Brazilian germ cell tumor protocol, GCT-91, evaluating two-agent chemotherapy with cisplatin and etoposide (PE). We now report on the clinical characteristics and survival of children and adolescents with germ cell tumors treated on this protocol. PATIENTS AND METHODS: From May 1991 to April 2000, 115 patients (106 assessable patients) were enrolled onto the Brazilian protocol with a diagnosis of germ cell tumor. RESULTS: Patients were treated with surgery only (n = 35) and chemotherapy (n = 71). Important prognostic factors included stage (P = .025), surgical procedure at diagnosis according to resectability (P < .032), and abnormal lactate dehydrogenase value at diagnosis (P < .001). CONCLUSION: The improvement in survival by the introduction of a standard protocol is an important achievement. This is of particular importance for smaller institutions with previous limited experience in the treatment of childhood germ cell tumors. In addition, the results of a two-agent regimen with PE were favorable (5-year overall survival rate is 83.3% for patients in the high-risk group [n = 36] who received PE v 58.8% for patients in the high-risk patients group who received PE plus ifosfamide, vinblastine, and bleomycin [n = 17; P = .017]). Thus for selected patients, complex three-agent regimens may not be necessary to achieve long-term survival, even for some patients with advanced disease.
PURPOSE: In 1988, we formed a consortium of Brazilian institutions to develop uniform standards for the diagnostic assessment and multidisciplinary treatment of children and adolescents with germ cell tumors. We also implemented the first childhood Brazilian germ cell tumor protocol, GCT-91, evaluating two-agent chemotherapy with cisplatin and etoposide (PE). We now report on the clinical characteristics and survival of children and adolescents with germ cell tumors treated on this protocol. PATIENTS AND METHODS: From May 1991 to April 2000, 115 patients (106 assessable patients) were enrolled onto the Brazilian protocol with a diagnosis of germ cell tumor. RESULTS:Patients were treated with surgery only (n = 35) and chemotherapy (n = 71). Important prognostic factors included stage (P = .025), surgical procedure at diagnosis according to resectability (P < .032), and abnormal lactate dehydrogenase value at diagnosis (P < .001). CONCLUSION: The improvement in survival by the introduction of a standard protocol is an important achievement. This is of particular importance for smaller institutions with previous limited experience in the treatment of childhood germ cell tumors. In addition, the results of a two-agent regimen with PE were favorable (5-year overall survival rate is 83.3% for patients in the high-risk group [n = 36] who received PE v 58.8% for patients in the high-risk patients group who received PE plus ifosfamide, vinblastine, and bleomycin [n = 17; P = .017]). Thus for selected patients, complex three-agent regimens may not be necessary to achieve long-term survival, even for some patients with advanced disease.
Authors: Bo Ci; Donghan M Yang; Mark Krailo; Caihong Xia; Bo Yao; Danni Luo; Qinbo Zhou; Guanghua Xiao; Lin Xu; Stephen X Skapek; Matthew M Murray; James F Amatruda; Lindsay Klosterkemper; Furqan Shaikh; Cecile Faure-Conter; Brice Fresneau; Samuel L Volchenboum; Sara Stoneham; Luiz Fernando Lopes; James Nicholson; A Lindsay Frazier; Yang Xie Journal: JCO Clin Cancer Inform Date: 2020-06
Authors: A Lindsay Frazier; Juliet P Hale; Carlos Rodriguez-Galindo; Ha Dang; Thomas Olson; Matthew J Murray; James F Amatruda; Claire Thornton; G Suren Arul; Deborah Billmire; Furqan Shaikh; Farzana Pashankar; Sara Stoneham; Mark Krailo; James C Nicholson Journal: J Clin Oncol Date: 2014-12-01 Impact factor: 44.544
Authors: Thomas A Olson; Matthew J Murray; Carlos Rodriguez-Galindo; James C Nicholson; Deborah F Billmire; Mark D Krailo; Ha M Dang; James F Amatruda; Claire M Thornton; G Suren Arul; Sara J Stoneham; Farzana Pashankar; Daniel Stark; Furqan Shaikh; David M Gershenson; Allan Covens; Jean Hurteau; Sally P Stenning; Darren R Feldman; Peter S Grimison; Robert A Huddart; Christopher Sweeney; Thomas Powles; Luiz Fernando Lopes; Simone dos Santos Agular; Girish Chinnaswamy; Sahar Khaleel; Sherif Abouelnaga; Juliet P Hale; A Lindsay Frazier Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Flavio Mavignier Cárcano; Daniel Onofre Vidal; André van Helvoort Lengert; Cristovam Scapulatempo Neto; Luisa Queiroz; Herlander Marques; Fátima Baltazar; Camila Maria da Silva Martinelli; Paula Soares; Eduardo Caetano Albino da Silva; Luiz Fernando Lopes; Rui Manuel Reis Journal: Tumour Biol Date: 2015-11-03
Authors: Ting Zhi Liu; Dong Sheng Zhang; Ying Liang; Ning Ning Zhou; Hong Fei Gao; Ke Jun Liu; Hai Ying Wu Journal: J Cancer Res Clin Oncol Date: 2011-08-18 Impact factor: 4.553
Authors: Sima Ferman; Marceli de Oliveira Santos; Juliana Moreira de Oliveira Ferreira; Rejane de Souza Reis; Julio Fernando Pinto Oliveira; Maria S Pombo-de-Oliveira; Beatriz de Camargo Journal: Clinics (Sao Paulo) Date: 2013 Impact factor: 2.365
Authors: Camila Maria da Silva Martinelli; André van Helvoort Lengert; Flavio Mavignier Cárcano; Eduardo Caetano Albino Silva; Mariana Brait; Luiz Fernando Lopes; Daniel Onofre Vidal Journal: Oncotarget Date: 2016-08-10